For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company has reported total income of Rs.826.40 crores for FY 2020-21
Subscribe To Our Newsletter & Stay Updated
